抗结核药的研发进展与非临床评价

The development and non-clinical evaluation of anti-tuberculosis drugs

结核病是人类十大死亡原因之一,是由结核杆菌引起的传染性疾病。当前结核病的防治越发困难,多药耐受性结核杆菌层出不穷,当前传统抗结核药物已经不能满足临床需要,新型抗结核药物成为当务之急。本文介绍近年抗结核药物的研发进展,非临床研究与评价的相关指导原则和重点。

Tuberculosis is one of the top ten causes of human death,which is an infectious disease caused by Mycobacterium tuberculosis.The prevention and treatment of tuberculosis is more and more difficult owing to multi-drug resistant Mycobacterium tuberculosis emerge in endlessly.A pressing matter is the new anti-tuberculosis drugs can not meet the clinical needs.This article introduces the development of anti-tuberculous drugs in recent years and the relevant guiding principles and key points in non-clinical study and evaluation.